Genetic Testing for Cancer: Balancing Benefits and Distress in Women's Health
"Understanding the Emotional Impact of BRCA1/2 Testing Without Pre-Test Counseling"
Genetic testing for cancer risk is becoming increasingly common, especially for women diagnosed with breast or ovarian cancer. These tests, particularly for BRCA1/2 genes, can reveal vital information that influences treatment decisions and preventive measures. However, receiving such information without adequate preparation can be emotionally challenging.
Traditionally, genetic testing involves pre-test counseling to help individuals understand the implications of the test results and cope with potential emotional distress. Yet, in many modern cancer clinics, BRCA1/2 testing is performed shortly after diagnosis, often without this crucial counseling step. This shift raises concerns about the psychological impact on women already grappling with a new cancer diagnosis.
A recent study published in Acta Oncologica sheds light on the experiences of women undergoing BRCA1/2 testing without pre-test genetic counseling. The research investigates the levels, course, and predictors of cancer-related distress in these women, providing valuable insights for healthcare professionals and individuals considering genetic testing.
Why Germline BRCA1/2 Testing Matters
Germline genetic testing (GT) can identify people with cancer-predisposition syndromes who may benefit from additional screening, risk-reducing or therapeutic interventions, and cascade testing for family members. BRCA1 and BRCA2 variants are associated with increased breast cancer risk; the supplied study excerpt reports estimates of 65–79% for BRCA1 and 61–77% for BRCA2. The nationwide study measured whether patients received germline BRCA1/2 testing within one year after diagnosis, using blood or saliva specimens and excluding people tested before diagnosis. Its follow-up data ran through March 31, 2021.
The Start of Clinical BRCA Testing
The supplied historical sources place the start of clinical BRCA testing in 1996, when Myriad Genetics made its commercial BRACAnalysis test available. One timeline reports that Myriad had played a role in sequencing BRCA1 and secured patents on the isolated BRCA1 and BRCA2 genes, granting it exclusive testing rights. The early test was described as costly and specialized, typically accessed by people with strong family histories of breast or ovarian cancer. Another source dates the identification of BRCA1 to 1990 and BRCA2 to 1994.
What the Study Revealed About Distress and Genetic Testing
The study, led by Hildegunn Høberg-Vetti and colleagues, involved 309 women—259 with breast cancer and 50 with ovarian cancer—who underwent BRCA1/2 testing shortly after their diagnosis. These women did not receive pre-test genetic counseling. The researchers measured cancer-related distress using the Impact of Event Scale (IES) before and after genetic testing to assess intrusion and avoidance symptoms.
- Overall Distress Levels: The study found that the women experienced moderate levels of intrusion and avoidance symptoms both before and after genetic testing.
- Distress Reduction: There was a statistically significant decline in these symptoms over time, suggesting that women gradually adapted to the information and their situation.
- Predictors of Higher Distress: Certain factors were associated with higher levels of distress:
- Younger age
- Shorter time since diagnosis
- Lower levels of perceived social support
- Diagnosis of ovarian cancer
- Higher levels of decisional conflict regarding genetic testing
- Living without a partner
Psychological Effects of Testing Support
A systematic review of patient decision-support resources for cancer-susceptibility testing reported that distress, anxiety, cancer worry, and depression generally remained below clinically relevant thresholds at baseline and follow-up. The review found no significant evidence of psychological harm from the pre-test resources it assessed. Separately, a study of people tested shortly after a cancer diagnosis reports cancer-related distress associated with a range of psycho-emotional symptoms, which decreased over time. The supplied sources therefore describe different contexts: effects of pre-test resources and distress around testing soon after diagnosis.
Access and Ethical Questions After 25 Years
A 2022 review marking 25 years since BRCA1/2 tests became publicly available describes testing as a precedent in genetic testing and the management of inherited cancer risk, as well as in bioethics. It notes that comprehensive guidelines now address BRCA1/2 testing and preventive measures for mutation carriers. Another supplied source reports that demand for hereditary breast cancer gene testing, including BRCA1 and BRCA2, has continued to increase alongside lower testing costs and greater public awareness. These excerpts describe expanding use and established guidance but do not provide quantified evidence of testing failures or harms.
Testing Methods and Clinical Uses
The supplied clinical-guideline summary describes recommendations intended to identify people who may benefit from genetic counseling and risk-reducing strategies, update germline and tumor-testing indications for PARP inhibitor-approved therapies, and guide personalized management of early and metastatic breast cancer. A separate overview lists sequencing, deletion/duplication analysis, and full-gene testing among methods used to test BRCA1 and BRCA2. It says test results can inform genetic counseling and treatment decisions by providing insight into risk for certain cancers. The sources describe complementary dimensions—clinical indications and laboratory methods—rather than comparing the performance of particular tests.
What This Means for Women and Healthcare Providers
The study underscores that women undergoing genetic testing shortly after a cancer diagnosis experience a moderate level of cancer-related distress. While this distress tends to decrease over time, certain factors can amplify it. Healthcare providers should be aware of these predictors—younger age, less social support, decisional conflict, and living without a partner—to identify women who may need additional support.
Testing Initiation in Oncology Practice
A 2024 report on the evolution of germline BRCA1/2 testing practices found a change in who most often initiated testing: 64% of surveyed respondents said medical oncologists most often initiated tests in 2023, compared with 29% in 2018. This survey finding suggests a larger role for medical oncologists in initiating germline testing over that period. The supplied USPSTF source provides patient and educational materials on BRCA-related cancer risk assessment, genetic counseling, and testing, including a JAMA patient page titled “Should I Be Tested for BRCA Mutations?”
Testing Patterns and Follow-Up
A retrospective cohort protocol describes linking BRCA1/2 genetic test results with administrative data to measure uptake of risk-reduction strategies and assess long-term cancer and non-cancer outcomes after testing. A separate real-world study assessed BRCA1/2 testing rates and patient characteristics among more than 6,000 adult women with HER2-negative advanced breast cancer in the United States and EU5 in 2015 and 2017. Another supplied study description says at least 50% of women with BRCA1/2 mutations go undiagnosed and reports an evaluation of testing differences across the United States, EU4, and Israel. The excerpts describe different study populations and objectives, so their findings should not be treated as a single population estimate.